Injectafer denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS's "Experimental" Denial for Injectafer Is a Strong Candidate for Reversal

Injectafer (ferric carboxymaltose) received FDA approval for the treatment of iron-deficiency anemia in adults who have an unsatisfactory response to or cannot tolerate oral iron, and for iron-deficiency anemia in adults with non-dialysis-dependent chronic kidney disease. An "experimental or investigational" denial from BlueCross BlueShield in this context is a significant red flag: a drug with established FDA approval and recognized use in evidence-based clinical guidelines does not meet the standard definition of experimental treatment. This type of denial most often reflects an administrative error, an outdated coverage policy, or a plan applying experimental criteria to an off-label indication without proper clinical review.

## Why This Denial Is Appealable

Under ACA §2719 and most state insurance regulations, a treatment cannot be classified as experimental if it has received FDA approval for the condition being treated and is supported by authoritative clinical evidence. If Injectafer is being prescribed for an FDA-approved indication, this denial category is legally and clinically unsupportable and is a strong appeal candidate. Even for off-label uses, the experimental classification may be inappropriate if the use is supported by the applicable hematology, nephrology, or gastroenterology society guidelines. Obtain the BCBS medical policy document that triggered the denial and compare it line by line against the FDA-approved labeling.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719 immediately. Request the specific BCBS medical policy document and the clinical rationale used to classify Injectafer as experimental.
• External review: Escalate to an IRO if denied internally; IROs apply the "generally accepted standards of medical practice" standard, under which an FDA-approved drug with guideline support virtually never qualifies as experimental. File within the approximately four-month window on your denial letter.
• Expedited review: Available if anemia is severe or symptomatic.

## Concrete Appeal Steps and Timeline

1. Request the specific BCBS medical policy and the clinical reviewer's basis for the experimental classification. 2. Obtain the FDA approval letter or the current prescribing label confirming approved status for the relevant indication. 3. Obtain a supporting statement from the prescribing physician and, if applicable, the applicable hematology or nephrology society guideline reference. 4. Submit the internal appeal with this documentation package; if denied, proceed immediately to IRO external review.

## Documentation to Gather

• FDA approval confirmation: A reference to the current Injectafer prescribing label confirming the approved indication that applies to this patient.
• Diagnosis confirmation: Lab results and clinical notes establishing the qualifying diagnosis.
• Guideline support: Reference to the applicable professional society guideline organization (e.g., the relevant hematology or nephrology society) recommending IV iron for this patient's condition.
• Prescriber medical-necessity letter: Explicit statement that the use is consistent with FDA approval and established clinical guidelines and therefore does not meet the definition of experimental.

## Criteria-Mapping Structure

Pull BCBS's definition of "experimental or investigational" from the denial notice or their medical policy. For each element of that definition — such as whether FDA approval exists, whether clinical evidence supports the use, whether the treatment is accepted standard of care — provide a direct documentary answer. Most experimental denials for FDA-approved drugs collapse at this first column.